Výsledky vyhledávání - "Zoé L. E. Van Kempen"

Akademický článek

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Autor: Carla Rodriguez-Mogeda, Zoë Y. G. J. van Lierop, Susanne M. A. van der Pol, Loet Coenen, Laura Hogenboom, Alwin Kamermans, Ernesto Rodriguez, Jack van Horssen, Zoé L. E. van Kempen, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Maarten E. Witte, Joep Killestein, Helga E. de Vries

Publikováno v: Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-17 (2023)

Abstract Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether c

Externí odkaz: https://doaj.org/article/3f86be80f38742afbf3232690c390a1c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination

Autor: Koos P. J. van Dam, Laura Hogenboom, Eileen W. Stalman, Laura Y. L. Kummer, Maurice Steenhuis, Jim B. D. Keijser, Anja ten Brinke, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Luuk Wieske, Filip Eftimov, Eva M. Strijbis, Joep Killestein, Zoé L. E. van Kempen

Publikováno v: Frontiers in Neurology, Vol 13 (2022)

IntroductionDuring the COVID-19 pandemic, certain disease modifying therapies (DMTs) used in multiple sclerosis (MS), such as anti-CD20 therapies, have been associated with decreased humoral responses after SARS-CoV-2 vaccination. Hybrid immunity, re

Externí odkaz: https://doaj.org/article/0b276eefa8dc4d3eaf40db874279d0cb

Zobrazit plný text záznamu

Akademický článek

The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis

Autor: Eline M. E. Coerver, Eva M. M. Strijbis, Laura F. Petzold, Zoé L. E. Van Kempen, Bas Jasperse, Frederik Barkhof, Cees B. M. Oudejans, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Joep Killestein

Publikováno v: Frontiers in Neurology, Vol 13 (2022)

BackgroundMyxovirus resistance protein A (MxA) is a protein that is upregulated by interferon-beta. Homeostatic MxA mRNA levels are potentially correlated with inflammatory disease activity in multiple sclerosis (MS) and could have an important role

Externí odkaz: https://doaj.org/article/2792785ccbba4c5595114d676a093686

Zobrazit plný text záznamu

Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

Autor: Alyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis, Jessica Nielsen, L G F Sinnige, Gert van Dijk, Christiaan M Roosendaal, Edo P J Arnoldus, Elske Hoitsma, Birgit I Lissenberg-Witte, Brigit A de Jong, Bob W van Oosten, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein

Publikováno v: Journal of Neurology, Neurosurgery and Psychiatry, 94(6), 482-486. BMJ Publishing Group
Toorop, A A, van Kempen, Z L E, Steenhuis, M, Nielsen, J, Sinnige, L G F, van Dijk, G, Roosendaal, C M, Arnoldus, E P J, Hoitsma, E, Lissenberg-Witte, B I, de Jong, B A, Oosten, B W V, Strijbis, E M M, Uitdehaag, B M J, Rispens, T & Killestein, J 2023, ' Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, pp. 482-486 . https://doi.org/10.1136/jnnp-2022-330467

BackgroundNatalizumab is effective in the treatment of multiple sclerosis (MS). In 2021, the European Medicines Agency approved the subcutaneous (SC) variant of natalizumab which can be used instead of intravenous administration. However, the course

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e7605d557613158f19e33be9532286f
http://www.scopus.com/inward/record.url?scp=85151850870&partnerID=8YFLogxK

Zobrazit plný text záznamu

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

Autor: Alyssa A Toorop, Laura Hogenboom, Karien Bloem, Merve Kocyigit, Nadine W M Commandeur, Anne Wijnants, Birgit I Lissenberg-Witte, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein, Zoé L E van Kempen

Publikováno v: Journal of Neurology, Neurosurgery and Psychiatry, 94(6):jnnp-2022-330793, 487-493. BMJ Publishing Group
Toorop, A A, Hogenboom, L, Bloem, K, Kocyigit, M, Commandeur, N W M, Wijnants, A, Lissenberg-Witte, B I, Strijbis, E M M, Uitdehaag, B M J, Rispens, T, Killestein, J & van Kempen, Z L E 2023, ' Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, jnnp-2022-330793, pp. 487-493 . https://doi.org/10.1136/jnnp-2022-330793
Journal of Neurology, Neurosurgery and Psychiatry. BMJ Publishing Group

BackgroundThe majority of patients with multiple sclerosis on ocrelizumab have B-cell depletion after standard interval dosing of 26 weeks. With B-cell-guided dosing patients receive their next dose when B-cell repopulation occurs. Prediction of B-ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05bf53014caba07c88a1fad212b74485
https://research.vumc.nl/en/publications/300cca69-bb4f-4bfb-9887-1f40967fbd8f

Zobrazit plný text záznamu

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants

Autor: Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, Laura Y L Kummer, Maurice Steenhuis, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Erik H Vogelzang, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Martijn Gerritsen, Irene E van der Horst-Bruinsma, Willem F Lems, Mike T Nurmohamed, Maarten Boers, Sofie Keijzer, Jim Keijser, Carolien van de Sandt, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Theo Rispens, Taco W Kuijpers, Gertjan Wolbink, Filip Eftimov, Rivka de Jongh, Lisan Kuijper, Mariel Duurland, Ruth Hagen, Jet van den Dijssel, Christine Kreher, Amelie Bos, Viriginia Palomares Cabeza, Veronique Konijn, George Elias, Juan Vallejo, Marrit van Gils, Tom Ashhurst, Sergey Nejentsev, Elham Mirfazeli

Publikováno v: The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier

Contains fulltext : 251784.pdf (Publisher’s version ) (Closed access) BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with imm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3619c889e4bb633a950bf507234c28e5
https://hdl.handle.net/11245.1/f610fc44-105d-4e73-957e-813043c700aa

Zobrazit plný text záznamu

Vaccination responses in B-cell-depleted multiple sclerosis patients:The role of drug pharmacokinetics

Autor: Joep Killestein, Zoé L. E. van Kempen

Publikováno v: Killestein, J & van Kempen, Z L E 2022, ' Vaccination responses in B-cell-depleted multiple sclerosis patients : The role of drug pharmacokinetics ', European Journal of Neurology, vol. 29, no. 11, pp. 3137-3138 . https://doi.org/10.1111/ene.15529
European Journal of Neurology, 29(11), 3137-3138. Wiley-Blackwell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca2ecd9e75f19456ff518f3a90a1fe45
https://research.vumc.nl/en/publications/7a6143d8-264c-4e2a-b029-df760ec1be4a

Zobrazit plný text záznamu

Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis

Autor: Eva M Strijbis, Eline Coerver, Jop Mostert, Zoé L E van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D Bowen, Gary Cutter, Marcus Koch

Publikováno v: Journal of Neurology, Neurosurgery & Psychiatry. :jnnp-2022

BackgroundFocal inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) diminishes with increasing age. Here we use patient-level data from randomised controlled trials (RCTs) of natalizumab treatment in RRMS to investigate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b333f661b0bda2f81356ee12411e1f7e
https://doi.org/10.1136/jnnp-2022-330887

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání